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The CRISPR/Cas9 system has revolutionized mammalian somatic cell genetics. Genome-wide functional screens using
CRISPR/Cas9-mediated knockout or dCas9 fusion-mediated inhibition/activation (CRISPRi/a) are powerful techniques
for discovering phenotype-associated gene function. We systematically assessed the DNA sequence features that contribute
to single guide RNA (sgRNA) efficiency in CRISPR-based screens. Leveraging the information from multiple designs, we
derived a new sequence model for predicting sgRNA efficiency in CRISPR/Cas9 knockout experiments. Our model con-
firmed known features and suggested new features including a preference for cytosine at the cleavage site. The model
was experimentally validated for sgRNA-mediated mutation rate and protein knockout efficiency. Tested on independent
data sets, the model achieved significant results in both positive and negative selection conditions and outperformed existing
models. We also found that the sequence preference for CRISPRi/a is substantially different from that for CRISPR/Cas9
knockout and propose a new model for predicting sgRNA efficiency in CRISPRi/a experiments. These results facilitate
the genome-wide design of improved sgRNA for both knockout and CRISPRi/a studies.
[Supplemental material is available for this article.]
The clustered regularly interspaced short palindromic repeats
(CRISPR) system allows efficient perturbation of gene regulation
in somatic cells and is increasingly being used for genome-wide
functional screens. The CRISPR-based screens fall into two catego-
ries: Cas9-mediated knockout and dCas9 fusion-mediated in-
hibition (CRISPRi) or activation (CRISPRa). In a CRISPR/Cas9
knockout system, the Cas9 nucleases induce double-strand breaks
on targeted genomic regions directed by single-guide RNAs
(sgRNAs). Indels produced at these breakpoints, as a result of an er-
ror-prone DNA repair mechanism, cause loss-of-function gene
knockouts at the DNA level (Jinek et al. 2012; Mali et al. 2013;
Yang et al. 2013). Alternatively, in the CRISPRi/a systems, catalyt-
ically inactive Cas9 (dCas9) proteins guided by sgRNAs enable the
localization of effector domains to repress or activate gene tran-
scription without modifying DNA (Gilbert et al. 2013; Qi et al.
2013). CRISPR/Cas9 knockout screens are better than previous
functional shRNA knockdown screens (Berns et al. 2004; Luo
et al. 2008) for the study of phenotypes that require complete in-
activation of genes (Shalem et al. 2014). CRISPRi/a are more flexi-
ble than shRNA in defining gene functions across a wider dynamic
range (Gilbert et al. 2014). In light of this, several sgRNA libraries
with diverse configurations have been developed for CRISPR/
Cas9 knockout or CRISPRi/a screens in human and mouse
(Gilbert et al. 2014; Koike-Yusa et al. 2014; Shalem et al. 2014;
Wang et al. 2014; Zhou et al. 2014; Konermann et al. 2015).
The design of sgRNA is critical to theCRISPR-based screens. In
a CRISPR system, an sgRNA contains a spacer sequence comple-
mentary to the targeted DNA sequence to guide the Cas9 or
dCas9 proteins to genomic targets. Several studies have investigat-
ed sgRNA off-target effects based on the alignment of spacer se-
quences to the genome (Hsu et al. 2013), dCas9 ChIP-seq (Wu
et al. 2014) and GUIDE-seq (Tsai et al. 2015). On the other hand,
DNA sequence also influences the efficiency of sgRNA at the on-
target genomic loci. It is well established that the Protospacer
Adjacent Motif (PAM) containing NGG consensus is required for
Cas9-DNA binding and cleavage in a CRISPR/Cas9 system
(Sternberg et al. 2014). A recent study showed that the sgRNA
efficiency depends on the purine/pyrimidine composition near
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the 3′ end of the spacer sequence (Wang et al. 2014). Moreover,
Doench et al. (2014) found the nucleotide composition of the
DNA downstream from the spacer target also contributes to the
sgRNA efficiency and proposed a predictive sequence model for
the design of CRISPR/Cas9 knockout experiments.
Despite these advances, it is unclearwhether the sequence fea-
tures reported in previous studies are reproducible across different
sgRNA library designs and genomes. Importantly, these features
were only tested on negative selections using CRISPR/Cas9 knock-
out systems, in which loss-of-function of a gene results in growth
disadvantage to the cells. Formodel justification andbroader appli-
cations, it is necessary to investigate their relevance to positive se-
lections in which gene perturbation promotes cell growth and
proliferation. Moreover, no sequence model has been developed
for predicting sgRNA efficiency in CRISPRi/a screens. To fill these
gaps, we systematically assessed the effect of sequence context on
sgRNA efficiency based on six published data sets (Table 1). Our
analysis led to the development of two computational models for
predicting sgRNA efficiency, corresponding to the CRISPR knock-
out and CRISPRi/a studies, respectively. To this end, our findings
and models facilitate the genome-wide design of improved
sgRNA for CRISPR-based screens.
Results
Selection of the efficient and inefficient sgRNAs in CRISPR/Cas9
knockout screens
To construct a predictive model, we took two steps to identify effi-
cient and inefficient sgRNAs in published data sets. First, for each
data set, we identified a list of essential genes whose deletion re-
sulted in a growth disadvantage in genome-wide CRISPR/Cas9
knockout screens. Second, the sgRNAs targeting these essential
genes were grouped into “efficient” and “inefficient” categories
based on their decline in abundance in the screens. We applied
our method to Wang and Koike-Yusa data (see Table 1). These
data sets have large numbers of sgRNAs per gene, which help to
identify reliable sets of essential genes.
The procedures of sgRNA selection and categorization are de-
picted in Figure 1. In Wang data, we identified 305 and 545 essen-
tial genes in the leukemia cell lines HL-60 and KBM-7, respectively
(Fig. 1A). Among them, 58 ribosomal and 163 nonribosomal genes
were essential in both cell lines. The essentiality of ribosomal genes
was also reported in other studies (Koike-Yusa et al. 2014; Shalem
et al. 2014), which established them as good positive controls in a
CRISPR/Cas9 knockout screen. In theWang library, each ribosom-
al gene was targeted by more than 20 sgRNAs, and each nonribo-
somal gene was targeted by 10 sgRNAs. Therefore, we split the
sgRNAs targeting common essential genes into “ribosomal” and
“nonribosomal” sets in order to take the difference of sgRNA sam-
ple space into consideration. We examined signals of sgRNAs by
comparing their abundance before and after selection. For the “ri-
bosomal” set, 731 (35.3%) sgRNAs showed more than twofold
depletion in both cell lines, indicating that they reproducibly
knocked out their target genes in the experiments and thus were
defined to be efficient. Four hundred thirty-eight (21.1%) failed
to show significant differences from control sgRNAs that do not
target any genomic locus and thus were defined to be inefficient.
The remaining sgRNAs showed relatively weak effects in both
cell lines, or had significant effects in only one cell line, and
were excluded from our analysis (Fig. 1B). For the “nonribosomal”
set, we selected 671 efficient and 237 inefficient sgRNAs using the
same criteria (Fig. 1C). In Koike-Yusa data, we identified 311 genes
that showed essentiality in two biological replicates of mouse em-
bryonic stem cells (mESCs) (Fig. 1D). Upon examining the signals
of sgRNAs targeting these genes, we found a bimodal distribution
of the relative sgRNA abundance in cell growth (Fig. 1E;
Supplemental Fig. 1). Categorization based on the bimodality re-
sulted in 830 efficient and 234 inefficient sgRNAs.
To this end, we selected three training sets of sgRNAs, namely
“ribosomal,” “nonribosomal,” and “mESC,” for the construction
of sequence models (Supplemental Table 1). The differences
among these sets reflect variations of sgRNA design, species, and
the experimental protocols.
Sequence features associated with sgRNA efficiency
in CRISPR/Cas9 knocking out
To explore sequence features that contribute to sgRNA efficiency,
we computed the log odds ratio of nucleotide frequency between
DNA sequences targeted by efficient and inefficient sgRNAs (Fig.
2A–C). These sequences are 40 bp in length, including the 19-bp
or 20-bp spacer targets as well as their 3′ and 5′ flanking DNAs.
All sequences were aligned at the PAM. The log odds ratios are cor-
related between the ribosomal and nonribosomal sgRNA sets (Fig.
2E) as well as between the two libraries developed independently
(Fig. 2F). The correlations indicate that many sequence features
are robust against the variation of sgRNA designs, species, and
the spacer length.Meanwhile, some features are discordant among
the three different sgRNA training sets. For example, guanine is
preferred at the 5′ end of the spacer in the “ribosomal” and “non-
ribosomal” sets, but not in the “mESC” set. This might be ascribed
Table 1. A collection of CRISPR screening data sets used in the study
Name used in this
paper Technique
Length of
spacer Number of sgRNAs per gene Type of selection Reference
Wang data CRISPR/Cas9 knockout 20 More than 20 for ribosomal genes;
10 for nonribosomal genes
Negative Wang et al. 2014
Koike-Yusa data CRISPR/Cas9 knockout 19 6 Positive/negative Koike-Yusa et al.
2014
Shalem data CRISPR/Cas9 knockout 20 3–5 Positive/negative Shalem et al.
2014
Zhou data CRISPR/Cas9 knockout 19–22 3–5 Positive Zhou et al. 2014
Gilbert data CRISPR/dCas9 inhibition
and activation
18–25 10 Positive/negative Gilbert et al. 2014
Konermann data CRISPR/dCas9 activation 20 3 Positive/negative Konermann et al.
2015
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to subtle differences in sgRNA design. If the 5′ end of the spacer is
not “G,”Wang et al. prepended a “G” for the expression of sgRNAs
from a U6 promoter, in the form of G(A/C/T)X19NGG; otherwise,
a form of GX19NGGwas taken without any prepended “G” (Wang
et al. 2014). Alternatively, Koike-Yusa et al. chose the form of
GX19NGG regardless of nucleotide composition at the 5′ end
(Koike-Yusa et al. 2014). These different designs of sgRNAs can re-
sult in the variation of the nucleotide pairings and 5′ overhang in
sgRNA-DNA binding structure, which could further impact sgRNA
efficiency.
To determine the reproducible features, we first selected
nucleotides that satisfy the following criteria across the three
training sets: (1) Signs of the odds ratios are concordant; and (2)
magnitudes of the odds ratios are above a threshold in all three
sgRNA sets, where the threshold was computed from a statistical
significance analysis (see Methods). To identify the dominating
nucleotide features, we next applied Elastic-Net, a penalized linear
regression model with proven utility in feature selection (Zou and
Hastie 2005). In our analysis, the predictor variable of Elastic-Net
was a binary vector representing the presence or absence of the
nucleotides selected based on the odds ratio, and the response
variable was 1 or −1 corresponding to the efficient and inefficient
sgRNAs, respectively. The union of the three sgRNA training
sets was used for Elastic-Net feature selection and parameter
estimation.
With this two-stage feature selection approach, we identified
28 sequence features, as shown in Figure 2D. Most features are lo-
cated within the spacer region. Our result confirmed several fea-
tures reported previously. First, guanines are strongly preferred at
the−1 and the−2 positions proximal to the PAM sequence, which
are associatedwith the sequence preference inCas9 loading (Wang
et al. 2014). Second, thymines are disfavored at the four positions
closest to the PAM, consistent with the fact thatmultiple uracils in
the spacer cause low sgRNA expression (Wu et al. 2014). Third, in
line with recent findings, the nucleotides downstream from the
PAM contribute to sgRNA efficiency, whereas the sequences up-
stream of the spacer have no significant effect (Doench et al.
2014). We also identified novel features that reproducibly impact
the sgRNA efficiency. For example, cytosine is preferred at the
−3 position, which is the DNA cleavage site by the CRISPR/Cas9
Figure 1. A schematic view of procedures for sgRNA selection and categorization. (A,B) Venn diagrams showing the overlap of essential genes between
human HL-60 and KBM-7 cells (A) and two biological replicates in mouse ESC JM8 cells (B). (C–E) Scatter plots showing the log2 fold-change of sgRNA
abundance in negative selection upon cell growth. (C) sgRNAs targeting essential ribosomal genes in Wang data. (D) sgRNAs targeting essential nonribo-
somal genes in Wang data. (E) sgRNAs targeting essential genes in Koike-Yusa data. The dashed lines represent the threshold chosen to determine efficient
and inefficient sgRNAs.
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complex (Cong et al. 2013). This feature might contribute to the
efficiency of cleavage or the introduction of mutation upon DNA
repair. Moreover, adenines are preferred from position −5 to
−12, and guanines are preferred at positions −14 to −17.
Experimental validation of the sequence model
in predicting mutation rates and protein knockout
efficiency
To experimentally test themodel in Figure 2D, we first assessed the
mutation rates mediated by a small set of sgRNAs targeting the
AAVS1 safe harbor genomic locus. We selected 10 targets with
low efficiency scores and 10 with high scores in the AAVS1 region
(Supplemental Table 3) and designed CRISPR/Cas9 lentivirus
based on the selected targets. Upon examining the transduced
293T cells, we found that sgRNAs with higher scores showed
much higher indel mutation rates than those with lower scores
(P = 1.9 × 10−5; t-test) (Fig. 3A). This confirmed that the sequence
features we selected have significant effect on the rate of on-target
mutation in a CRISPR/Cas9 system.
Wenext tested if the sequencemodel is informative to predict
knockout efficiency on the protein expression level. We designed
Figure 2. Preference of nucleotide sequences that impact sgRNA efficiency. (A–C) Logos showing the sequence preference of the three sgRNA sets de-
fined in Figure 1. The height of the nucleotides represents the log odds ratio of nucleotide frequency between efficient and inefficient sgRNAs. (D) A logo
showing the selected features that reproducibly impact sgRNA efficiency in the three sgRNA sets. The height of the nucleotides represents the coefficients
computed from the Elastic-Net. (E,F) Scatter plots showing the correlation of sequence preference for sgRNAs targeting ribosomal versus nonribosomal
genes in Wang data (E) and sgRNAs in Wang data versus Koike-Yusa data (F ). Each dot represents a nucleotide in a 40-bp region centered by the spacer.
The sequence preference is measured as the log2 odds ratio of nucleotide frequency between efficient and inefficient sgRNAs.
Figure 3. Experimental validation of the sequencemodel in predicting sgRNA efficiency. (A) A SURVEYOR gel picture (top) and a bar chart (bottom) show-
ing the indel rates of the sgRNAs predicted to be inefficient (low sequence score) or efficient (high sequence score). The sgRNAs were selected to target the
AAVS1 locus. The experiment was conducted in 293T cells. (B) A scatter plot showing the correlation of the predicted sequence scores and the protein
knockout efficiency for sgRNAs targeting AR and FOXA1 in LNCaP-abl cells. The knockout efficiency is measured as the percentage of reduction in protein
level upon sgRNA infection.
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sgRNAs against AR and FOXA1 and tested them in prostate cancer
LNCaP-abl cells using Western blot to assay protein expression
(Supplemental Fig. 2; Supplemental Table 4). The predicted
sgRNA efficiency score showed strong positive correlation with
the protein knockout efficiency (P = 9.0 × 10−6; Pearson’s correla-
tion) (Fig. 3B), where the efficient and inefficient sgRNAs can be
clearly separated. Our result suggested a cutoff of zero as a reason-
able threshold for sgRNA classification, in line with the configura-
tions in model training, in which the values of 1 and −1 were
assigned to efficient and inefficient sgRNAs, respectively.
Predictive power of the sequence model in negative
selection screens
With the satisfactory results in the low-throughput validation
mentioned above, we next assessed the predictive power of the se-
quence model using published high-throughput CRISPR/Cas9
knockout screening data. We designed four schemes for this in sil-
ico validation. First, randomized threefold cross validationwas car-
riedouton the categorized sgRNAs in the ribosomal set to assess the
predictive power under identical experimental settings; second,
the Elastic-Net model was trained on the ribosomal set and tested
on thenonribosomal set, ofwhich the resultwas expected to reflect
the within-library performance under different configurations
of sgRNA sampling; third, to evaluate the inter-library and inter-
species performance, the model was trained on the union of ribo-
somal and nonribosomal sets in human and tested on the mESC
set; last, the model was trained on the union of all three sets and
tested on an independent library of sgRNAs (Shalem et al. 2014).
The sgRNA list used in the fourth validation was compiled
by Doench et al. (2014) to assess their model in predicting sgRNA
“activity,” a measure analogous to the “efficiency” defined in this
paper. We achieved reasonable predictive power in all four valida-
tions, in which the Area Under Curve (AUC) scores were above
0.7 in Receiver Operating Characteristic (ROC) (Fig. 4A,B). Our
model also outperformed the model proposed by Doench et al.
(2014) in predicting sgRNA activity (Fig. 4B). With a cutoff thresh-
old of zero, 50%–60% of the inefficient sgRNAs are predictable, at
the cost of 10%–20% of efficient sgRNAs misclassified.
Since the sequence model was trained based on the sgRNAs
targeting common essential genes, we further tested if the model
is applicable to the sgRNAs targeting cell-type-specific essential
genes. We examined the correlations between sequence scores
and the relative sgRNA abundances for ABL1 and BCR, two
Figure 4. Predicting sgRNA efficiency from sequence context in CRISPR/Cas9 knockout screens. (A) ROC curves showing the predictive power of the
proposed model. (Red) Threefold cross-validation on the sgRNAs targeting ribosomal genes in Wang data; (blue) trained on ribosomal genes, and tested
on nonribosomal genes in Wang data; (green) trained on Wang data, and tested on Koike-Yusa data. The black error bars on the red curve represent stan-
dard deviations computed from 10 iterations of random sampling in cross-validation. (B) ROC curves comparing the performance of the proposed model
and the Doench et al. (2014) model in predicting sgRNA efficiency in Shalem data. (C) Scatter plot showing the correlation between the predicted se-
quence score and the relative sgRNA abundance for ABL1 and BCR in KBM-7 cells. The P-values were computed based on the Pearson correlation test.
(D) Box plot showing the distributions of correlations between sequence scores and relative sgRNA abundances for essential and nonessential genes in
KBM-7. The distribution of random background was computed by permuting the sequence scores within each gene in the data set. (E) Distributions of
relative sgRNA abundances in KBM-7 cells, where the sgRNAs were categorized based on the predicted efficiency and the essentiality of their targeted
genes.
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genes coding for an oncogenic fusion protein in KBM-7 cells
(Andersson et al. 1995). For both genes, significant correlations
were observed between predicted sgRNA efficiency and the chang-
es of sgRNAabundance in the screen (Fig. 4C). To evaluatewhether
sequence-specific sgRNA efficiency also influences sgRNAs target-
ing nonessential genes, we compared distributions of the correla-
tions for essential and nonessential genes identified in KBM-7
(Fig. 4D) or HL-60 (Supplemental Fig. 3). As expected, sequence
scores and relative sgRNA abundances are in strong negative corre-
lation for essential genes. Meanwhile, there are weak but statisti-
cally significant negative correlations for nonessential genes,
which might be attributed to (1) the false negatives in identifying
essential genes; (2) decreased cell growth due to intrinsic toxicity
of DNA cleavage, similar to the toxicity reported on Cre recombi-
nase (Silver and Livingston 2001); and/or (3) potential off-target
effects of sgRNAs. Notably, no correlation was observed for those
control sgRNAs lacking genomic targets (Supplemental Fig. 4),
consistent with the requirement of chromatin binding for an
sgRNA to exert its cell functions.
We next checked if a proper selection of sgRNAs based on the
prediction result could refine the sgRNA pool. As shown in Figure
4E, the signals of essential and nonessential genes are not well
separable with the predicted inefficient sgRNAs. In contrast, the
efficient sgRNAs produced highly informative signals that distin-
guish essential genes from others. This indicates that the removal
of inefficient sgRNAs can reduce the number of required sgRNAs
without compromising the sensitivity of the CRISPR/Cas9 knock-
out screens.
Generality of the sequence model in positive selection screens
Our model was trained based on the sgRNAs targeting essential
genes that were negatively selected in the experiments. We next
asked if the model is applicable to positive selection screens. To
answer this, we curated four lists of genes involved in the resistance
to drug or toxin treatments, including the BRAF inhibitor
Vemurafenib (PLX) in melanoma A375 cells (Shalem et al. 2014),
alpha-toxin and 6-thioguanine (6TG) in mouse embryonic stem
cells (Koike-Yusa et al. 2014), and anthrax toxin in HeLa cells
(Supplemental Table 5; Zhou et al. 2014). The sgRNAs targeting
these genes were categorized based on the reproducibility of posi-
tive selection, i.e., the increase of the sgRNA abundance in multi-
ple biological replicates upon treatments. As shown in Figure 5A–E,
the predicted efficient sgRNAs expressed higher reproducibility of
positive selection in all the experiments, indicating our model’s
applicability to positive selection screens. Next, we assessed the
predictive power of our model and the model by Doench et al.
(2014) on the curated sgRNA sets, in which the sgRNAs “selected
in all replicates”were defined as positives and the sgRNAs “not se-
lected in any replicates” were defined as negatives. Our model
Figure 5. Assessment of the sequence models in predicting sgRNA efficiency in positive selection experiments. (A–E) Bar charts showing the capability of
selection and the experimental reproducibility for predicted efficient and inefficient sgRNAs. The tested sgRNAs target the genes known to be involved in
the resistance to different drug treatment or external stimulus. (F ) ROC curves comparing the performance of the proposed model and the Doench et al.
(2014) model in predicting sgRNA efficiency in positive selection experiments. In the evaluation, the positive test set consists of the sgRNAs selected in all
replicates in B–E; and the negative test set consists of those not selected in B–E.
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achieved an AUC score of 0.711 and significantly outperformed
the Doench et al. (2014) model (Fig. 5F). Notably, 42.3% of the ef-
ficient sgRNAs contain a cytosine at the cleavage site, in compari-
son with 25.9% for inefficient sgRNAs, suggesting this novel
feature also contributes to sgRNA efficiency in positive selections.
Our prediction is therefore consistent with the phenotype in
both positive and negative selections, where the abundance of ef-
ficient sgRNAs is expected to change in opposite directions. This
line of evidence, together with our validation results on mutation
rate and protein knockout efficiency, confirmed that the selected
sequence features impact cell phenotype mainly through the
loss-of-function of the target genes, but not through their intrinsic
toxicity on cell growth.
Sequence-specific sgRNA efficiency in CRISPRi/a screens
Recently, Gilbert et al. (2014) proposed to use a CRISPRi/a system
for genome-wide functional screens. To explore the impact of se-
quence context on the efficiency of sgRNAs in their study, we
selected 6624 sgRNAs targeting the 500 most essential genes in
the published CRISPRi negative selection data in K562 cells
(Supplemental Table 6). These sgRNAs were grouped into “effi-
cient” and “inefficient” based on the phenotype scores that mea-
sure the relative sgRNA abundance (Fig. 6A).
Since the spacers have variable lengths in this data set, we first
examined the percentage of efficient sgRNAs with different spacer
lengths. We found sgRNAs with a spacer length of 19 nt have the
highest efficiency, slightly better than those with 20 nt spacers
(Fig. 6B). Despite the previous report that truncated sgRNAs with
17- to 18-nt spacers have less off-target effects (Fu et al. 2014),
shorter spacers showed less on-target effect in comparison with
19-nt or 20-nt spacers. To remove the confounding effect of spacer
length, we computed the log odds ratio of nucleotide frequency
for the efficient and inefficient sgRNAs based on different
spacer lengths (Fig. 6C). Similar to CRISPR/Cas9 knockout, the
CRISPRi/a system prefers purines at most of the nucleotides in
the spacer. However, there are also significant differences. In
CRISPR/Cas9, a small number of nucleotides, mostly adjacent to
Figure 6. Preference of the length and sequence context of spacers in CRISPR/dCas9 inhibition (CRISPRi) and activation (CRISPRa) screens. (A)
Distribution of phenotype scores (Gilbert et al. 2014) for sgRNAs targeting the top 500 essential genes and the control sgRNAs in CRISPRi experiments.
The dashed line represents the threshold chosen to determine efficient and inefficient sgRNAs. (B) A bar chart showing the effect of spacer length on
sgRNA efficiency. (C) Logos showing the sequence preference of spacers. The height of the nucleotides represents the log odds ratio of nucleotide frequen-
cy between efficient and inefficient sgRNAs. The nucleotide at the 5′ end of the spacers is fixed to be guanines in the library design and is excluded from the
logos. (D) Bar charts comparing the performance of CRISPRi model and CRISPR/Cas9 KO model in predicting sgRNA efficiency in CRISPRi negative selec-
tion, CRISPRi positive selection upon CTx-DTA treatment, and CRISPRa negative selections in Gilbert data and Konermann data. The length of spacers is
20 nt. Cross-validation was used to assess the performance of the CRISPRi model in the CRISPRi negative selection experiment. The error bars represent the
standard deviations in 10 iterations of threefold cross validation. The P-value was computed using a paired t-test.
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the PAM, dominate the sequence preference (Fig. 2A–D). In con-
trast, many nucleotides throughout the spacer region collectively
contribute to sgRNA efficiency in the CRISPR/dCas9 system. The
disparity can be ascribed to several factors. First, unlike CRISPR/
Cas9 knockout, CRISPRi/a does not introduce DNA cleavage,
which explains the observation of no cytosine enrichment at the
−3 position. Second, the structural and functional differences be-
tween Cas9 and dCas9 can lead to diverse sequence preference
for protein loading and the initiation of gRNA-DNA pairing.
Third, the effector domains that play crucial roles for gene pertur-
bation in CRISPRi/a do not exist in a CRISPR/Cas9 system. Fourth,
the U6 promoter and the sgRNA constant region are different be-
tween the Gilbert et al. (2014) design and other platforms (Chen
et al. 2013). Last but not least, CRISPRi/a mainly targets gene pro-
moters, where the sequence contexts are substantially different
from those in coding regions.
To evaluate the sequence-specific sgRNA efficiency in
CRISPRi/a, we designed linear classifiers using the Elastic-Net
and validated the classifiers with four settings: (1) threefold
cross-validation on the sgRNAs targeting negatively selected essen-
tial genes in the CRISPRi experiment; (2) training on the essential
genes and testing on the positively selected genes upon CTx-DTA
treatment; (3) training on the essential genes in the CRISPRi exper-
iment and testing on the growth-inhibiting genes in CRISPRa data
(Gilbert et al. 2014); and (4) repeating the training process in (3)
and testing in Konermann CRISPRa data (Konermann et al.
2015). We achieved ROC-AUC scores of 0.6–0.65 in the four vali-
dations, which indicated that the sequence model is applicable
to positive selections, CRISPRa experiments, as well as to the
CRISPRi/a systems of independent designs (Fig. 6D). There is less
predictive power when applying the CRISPR/Cas9 knockout mod-
el on CRISPRi/a data (ROC-AUC < 0.6). Notably, comparing with
the higher predictive power in CRISPR/Cas9 knockout screens
(ROC-AUC> 0.7), we found the sgRNA efficiency in CRISPRi/a to
be less dependent on the sequence context. It is possible that tran-
scription factor binding and chromatin states at the target sites of
CRISPRi/a influence knockdown efficiency, which cannot be ex-
plained by the sequence context alone.
Discussion
Wehave systematically assessed the contributions of sequence fea-
tures to sgRNAefficiencies, which are critical to the performance of
genome-wide CRISPR based functional screens. To achieve suffi-
cient statistical power, at leasthundredsof sgRNAsamplesareneed-
ed for the analysis (see Supplemental Material). Therefore, we
sought to collect samples frompublished high-throughput screen-
ing data sets. In the study of CRISPR/Cas9 knockout screens, we
used an integrative method to select sequence features that are re-
producible among different data sets. Such a method is helpful to
improve the robustness of the sequence model for the prediction
in various applications. In addition to known features reportedpre-
viously, our model suggested novel features to better understand
themolecularmechanismof theCRISPR/Cas9 genome-editing sys-
tems.We demonstrated the predictive power of ourmodel through
multiple validations—including tests on independent designs,
various cell types, and different growth selections—which support
the robustness of the model for customized sgRNAs designs.
Despite these findings, ∼40% of inefficient sgRNAs are not
predictable with our sequence model, which can be ascribed to
sgRNA secondary structure, chromatin structure, exon-skipping
during transcription, strand and location (e.g., 5′ versus 3′ end)
of sgRNA target relative to the gene, possibly nonlinear interactive
effects among different positions, as well as the sgRNA-specific
likelihood of a frame shift (Doench et al. 2014; Wang et al.
2014). The performance of the model might be further improved
by including these other features in the future. Another limitation
of our study is the relatively small number of cell lines (five for
CRISPR/Cas9 KO and two for CRISRPi/a) and library designs for
the training and testing of our computational model. It is possible
that some cell-specific sequence preferences were missed in our
study. With the expected growth of CRISPR data sets, more com-
prehensive and systematic assessment could be helpful to refine
the predictive model.
It is worth noting that selection against sgRNAs targeting
nonessential genes is also dependent on the sgRNA efficiency in
amoderate but statistically significantmanner. This can be partial-
ly explained by false negatives in identifying essential genes and
the potential off-target effects of sgRNAs. On the other hand, it
has been reported that the DNA cleavage induced by Cre re-
combinase results in growth retardation of cells that is indepen-
dent of the targeted genomic loci (Silver and Livingston 2001).
Therefore, it is possible that the on-target DNA cleavage intro-
duced by CRISPR/Cas9 system might have similar toxicity on
cell growth. Future work is needed to validate this hypothesis,
and to normalize the CRISPR/Cas9 screen data against the
sgRNA toxicity and efficiency.
In this study, we found that the sequence preference in
CRISPRi/a is significantly different from that in CRISPR/Cas9
knockout. This is expected since the CRISPRi/a system uses a dis-
tinct mechanism to perturb gene function without introducing
DNA cleavage. We note that our analysis is based on published
data sets in which coding regions were chosen for CRISPR/Cas9
targeting and promoters were chosen for CRISPRi/a targeting.
The difference of nucleotide composition between the coding re-
gions and the promoters, such as codon structure and GC enrich-
ment, might introduce bias to our analysis. It would be interesting
to compare these two systems with an unbiased design in future
study. Despite this, our validation result on AAVS1 locus suggests
that the CRISPR/Cas9 knockout model is also applicable to non-
coding regions.
The models proposed in this study focus on sgRNA sensitiv-
ity. Meanwhile, the specificity of sgRNAs should also be consid-
ered when designing an sgRNA pool. Wu et al. (2014) observed
numerous off-target binding sites at the genomic loci with suffi-
cient sequence similarity to the sgRNA spacer and reported that
thymine-rich sgRNA spacers have fewer off-target sites than others
due to the low level of sgRNA expression and the scarcity of com-
plementary sites in accessible chromatin. This finding, however, is
not contradictory to our model showing disfavored thymine near
the 3′ end of sgRNA target, but rather reflects the requirement of an
appropriate tradeoff between specificity and sensitivity in sgRNA
design. Surprisingly, a recent study showed that the majority of
off-target cleavage sites are undetectable using existing computa-
tional methods or dCas9 ChIP-seq (Tsai et al. 2015). Further stud-
ies are needed to address both sgRNA efficiency and off-target
effect for optimal sgRNA designs.
Methods
Preprocessing
Suppose there are N experiments performed on a set ofM sgRNAs,
and the read count of sgRNA i on experiment j is xij,
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1 ≤ i ≤ M, 1 ≤ j ≤ N. To normalize against the sequencing depth
and the global trend of cell growth, we assume that a majority of
the sgRNA-targeted genes have no effect on cell growth.
Therefore, we adjusted read count x′ij = xij/sj, where sj is the medi-
an read count of all sgRNAs in the jth experiment. This median
normalization approach was applied to Wang, Koike-Yusa,
Shalem, and Konermann data. For Zhou data, the median read
count was zero in the experiments after positive selection since
the strength of selection was very strong so that a majority of the
sgRNAs were completely depleted except a few that contribute to
drug resistance. In this case, we set the normalization factor sj to
be the average read count of all sgRNAs. Normalization in such a
waymight introduce bias to the estimation of relative sgRNAabun-
dance, but it will not affect the conclusion drawn from Figure 5E
because the bias is a constant added to all sgRNAs.
Next, we compute the relative sgRNA abundance between
two experiments. Suppose x′ij and x
′
ik are the adjusted read counts
of the ith sgRNA in the jth and kth experiments, the relative
sgRNA abundance is computed as the log2-transformed ratio
rijk = log2
x′ij + e
x′ ik + e
( )
where ɛ is a small positive value to avoid large variation due to low
read counts, and it was set to be 0.05.
For negative selection inWang data, the relative sgRNA abun-
dancewas computed by comparing the cell population after 12 cell
doublings against the initial seeding states in HL-60 and KBM-7
cells, respectively. For negative selection in Koike-Yusa’s data set,
the transfected mESCs cultured for 6–7 d were compared against
plasmid control. For positive selection in Koike-Yusa data, the
mESCs treated with toxin were compared against plasmid control.
For positive selection in Shalem data, A375 cells with PLX treat-
ment were compared against the population without PLX treat-
ment at day 7 and day 14. For positive selection in Zhou data,
HeLa cells after three rounds of toxin treatment were compared
against plasmid control. For negative selection in Konermann
CRISPRa data, A375 cells withDMSO treatmentwere compared be-
tween day 21 and day 3. The negative selection data by Shalem
et al. (2014) and the CRISPRi/a data by Gilbert et al. (2014) were
not preprocessed, as the phenotypic measure of the sgRNAs were
retrieved directly from their studies.
Selecting phenotype-associated genes
For the CRISPR/Cas9 knockout data sets, we ran the beta-0.1 ver-
sion of RIGER (http://www.broadinstitute.org/cancer/software/
rnai/riger/) to call the negatively selected genes (Luo et al. 2008).
In the configurations of RIGER, the measures of relative sgRNA
abundance were used to rank the sgRNAs, and a Kolmogorov-
Smirnov test was chosen to determine the significant genes. The
threshold of P-values was set to be 0.001. The positively selected
genes in Figure 5 were collected based on experimental validations
in the original studies (Koike-Yusa et al. 2014; Shalem et al. 2014;
Zhou et al. 2014), and a cutoff threshold of two folds in relative
sgRNA abundance were used to determine efficient and inefficient
sgRNAs. The phenotype-associated genes in the CRISPRi/a data set
were retrieved from the original paper (Gilbert et al. 2013).
Thresholds for identifying efficient and inefficient sgRNAs
As shown in Figure 1, we used different thresholds for identifying
efficient and inefficient sgRNAs in Wang data and in Koike-Yusa
data. This is because the sgRNAs targeting essential genes in
Wang data and Koike-Yusa data have different distributions of
log ratios due to the variance of cell growth rate, Cas9 activity,
and the depth of selection in the experiments. In Wang data, the
sgRNAs with a log ratio smaller than −1.0 in both HL-60 and
KBM-7 were identified to be efficient, and the thresholds for inef-
ficient sgRNAs are in the fifth percentile of the log ratios of control
sgRNAs in HL-60 and KBM-7. The thresholds in Koike-Yusa data
were determined based on the bimodal distribution of signals
(Supplemental Fig. 1). Notably, when the thresholds in Koike-
Yusa data were set to be identical to those used in Wang data, we
observed little variation of nucleotide frequency (r = 0.96).
Therefore, our sequence model is insensitive to the threshold
chosen.
Extracting sequence features
For Wang, Koike-Yusa, and Shalem data, sequences of spacer tar-
gets and their flanking regions were extracted from hg19 or
mm9 genome assembly. Since the length of sgRNA spacers varies
from 18 bps to 22 bps in the Zhou et al. (2014) platform, we
mapped the spacer sequences to hg19 assembly to find the geno-
mic loci of the targets and extracted the 40-bp sequence (spacer
+ 3′ + 5′) based on the aligned PAM loci. The sequences in
CRISPRi/a data were retrieved from the original paper (Gilbert
et al. 2014; Konermann et al. 2015).
Determining reproducible features in CRISPR/Cas9
knockout screens
To measure the sequence preference, we computed the log2 odds
ratio of nucleotide frequency between efficient and inefficient
sgRNAs, for the “ribosomal,” “nonribosomal,” and “mESC” sets.
Let s1i , s
2
i , and s
3
i represent the log2 odds ratios for the ith nucleotide
computed from the 3 sgRNA sets, we define a score si as
si = sgn(s
1
i ) ×min( s1i
∣∣ ∣∣, s2i∣∣ ∣∣, s3i∣∣ ∣∣) if sgn(s1i ) = sgn(s2i ) = sgn(s3i )
0 else
{
where sgn(s) is the sign of s; and |s| is the magnitude of s.
To determine the background distribution of si, we randomly
permuted the sgRNAs in the efficient and inefficient categories
within each set and computed si based on the permuted data.
This results in an empirical null distribution of si. A threshold T
was then set to be at the 95% confidence interval of the null distri-
bution, and the nucleotides with |si| . T were selected as repro-
ducible features.
The Elastic-Net model
SupposeX = [X1,X2, . . . ,XN ]T is the set of encoded sequence vec-
tors, andY = [y1, y2, . . . , yN ]T is the set of outputs representing the
efficiency of sgRNAs, where N is the number of sgRNA samples for
training. Let M be the length of the input vectors, the Elastic-Net
model computes the parameters b = [b1,b2, . . . ,bM ]T that mini-
mize an objective function E
E = Y − bTX 2 + l(a b 1 + (1− a) b 2)∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣
where α and λ are parameters estimated using cross validation,
||b||1 =∑
i
bi
∣∣ ∣∣, and ||b||2 =∑
i
b2i . We used the glmnet R package
to implement the Elastic-Net.
When training the Elastic-Nets for sequence feature selection,
we found the optimal α to be 1.0 for CRISPR/Cas9 knockouts and
0.0 for CRISPRi/a (Supplemental Figs. 5, 6). We note that the
Elastic-Net is equivalent to the Least Absolute Shrinkage and
Selection Operator (LASSO) when α = 1.0 (Tibshirani 1996) and
is equivalent to the Ridge regression model when α = 0.0
(Tikhonov and Arsenin 1977). In practice, the LASSO model is
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preferred to select a small number of features from a large amount
of candidates, whereas the Ridge regression is more relevant in sit-
uations when many features cumulatively contribute to the re-
sponse. Therefore, our result on the selection of optimal α is
explainable since the sgRNA efficiency depends on fewer sequence
features in Cas9 knockout in comparison with that in CRISPRi/a.
Application of previous model
To apply the Doench et al. (2014) model, we downloaded the py-
thon script at http://www.broadinstitute.org/rnai/public/analysis-
tools/sgrna-design. For fair comparison, the tested sgRNA targets
and our regression model (Fig. 2D) were truncated into a 30-bp se-
quence harboring the spacer target, following the requirement in
the Doench et al. (2014) model.
Cell lines and cell culture
The LNCaP-abl (abl) cell line was provided by Zoran Culig
(Innsbruck Medical University, Austria). The abl cells were cul-
tured in the RPMI 1640 phenol red-free medium supplemented
with 10% charcoal/dextran- treated fetal bovine serum, 2 mM glu-
tamine, 100 µg/mL penicillin, and 100 units/mL streptomycin for
the experiments. The 293T cells obtained from the American Type
Culture Collectionweremaintained in DMEMmedia supplement-
ed with 10% fetal bovine serum, glutamine, and penicillin-
streptomycin.
Plasmid construction, lentivirus production, and transduction
into human cells
Twenty sgRNAs targeting the AAVS1 locus, nine sgRNAs targeting
the AR gene, and six sgRNAs targeting the FOXA1 gene were de-
signed and selected according to our prediction of sgRNA efficient
scores. The sgRNA oligos were cloned into lentiCRISPRv2 plasmid
(Addgene) as previously described (Shalem et al. 2014). Each plas-
mid containing inserted sgRNA sequencewas verified using Sanger
sequencing. To make lentivirus, the constructed lentiCRISPRv2
plasmids were cotransfected into 293T cells with packaging plas-
mids pMD2.G and psPAX2 (Addgene) using X-tremeGENE HP
DNA Transfection Reagent (Roche) in 12-well plates according to
the manufacturer’s instructions. These 35 types of packaged lenti-
virus were then transduced into 293T and LNCaP-abl cells using
24-well plates, followedby puromycin selection for 3 d. The surviv-
ing cells were maintained for another 3 d before isolation of the
DNA and proteins.
SURVEYOR nuclease assay and Western blot
The DNA fragments of the AASV1 locus were amplified from ex-
tracted genomic DNA by PCR using the Q5 high-fidelity DNA po-
lymerases (NEB). SURVEYOR nuclease assays were subsequently
performed according to the manufacturer’s instructions (Trans ge-
nomic). The indel mutation rates were calculated as previously de-
scribed (Ran et al. 2013).Western Blot forAR and FOXA1 knockout
in LNCaP-abl cells by different sgRNAswas carried out usingwhole
cell lysates as described previously (Xu et al. 2012), The antibody
used for immunoprecipitation was anti-AR (N-20, Santa Cruz
Biotechnology) and anti-FOXA1 (ab23738, Abcam), or anti-
GAPDH (sc-25778, Santa Cruz Biotechnology). The images were
analyzed using ImageJ (Schneider et al. 2012).
Software availability
A software package named Spacer Scoring for CRISPR (SSC) was
developed for predicting sgRNA efficiency from genomic sequenc-
es. The SSC source codes are available in the SupplementalMaterial
and at http://sourceforge.net/projects/spacerscoringcrispr/. Aweb-
based application is available at http://crispr.dfci.harvard.edu/SSC.
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